Antibody-drug conjugates (ADCs) have emerged as one of the busiest and most crowded niches within oncology, given their potential to use an antibody to ferry a potent cytotoxic payload toward tumor cells. The class now spans about 15 FDA-approved products, and the segment is growing steadily. Evaluate Pharma projects the ADC category will reach $57…
How Nucleai’s spatial biology tech aims to accelerate drug development
Nucleai, founded in 2018 and based in Chicago and Tel Aviv, is pioneering new ground in spatial biology. Its AI-powered technology provides crucial context for tumor analysis, moving beyond traditional, static biopsy images to highlight cellular interactions that influence disease progression and treatment response. Innovation, in many cases, happens at the overlap of different domains,…

